Howard A. Burris

机构：Sarah Cannon · ORCID：0000-0002-1501-2931

发表论文 1151 篇 · 总被引 72908 次 · h-index 117

代表论文

• The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial (2025 · Clinical Cancer Research · 被引 7)
• Clinical Presentation of MTAP Deletions in Real-World Settings: Lessons for the Clinical Development of Novel Targeted Therapies (2025 · JCO Precision Oncology · 被引 4)
• Clinical Research in Community Oncology: Advancing Cancer Care Through Localized Clinical Trials (2026 · JCO Oncology Practice · 被引 1)
• Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma (2026 · Future Oncology · 被引 1)
• Supplementary Figure 8 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study (2026)
• Supplementary Table 4 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study (2026)